Program News
News and stories about the UNC Lineberger Cellular Immunotherapy Program
-
UNC Lineberger’s Advanced Cellular Therapeutics Facility earns accreditation
The Foundation for the Accreditation of Cellular Therapy awarded accreditation without any deficiency citations to UNC Lineberger’s Advanced Cellular Therapeutics Facility.
-
Three drug cocktail shows potential to boost CAR-T cancer therapy
Gianpietro Dotti, MD, and colleagues report in Nature Immunology they have identified a cocktail of three different drugs that can be used to generate more robust CAR-Ts to fight cancer.
-
Serody and Yeh honored with Battle Distinguished Cancer Research Award
Jonathan Serody, MD, and Jen Jen Yeh, MD, were named the 2023 recipients of the Hyman L. Battle Distinguished Cancer Research Award, recognizing their significant scientific achievements.
-
Immune cell transformation can influence stem cell transplant success in cancer patients
Jonathan Serody, MD, Ian Davis, MD, PhD, and colleagues report ILC2s can change functions after a patient receives stem cells, thereby preventing a healthy rebuilding of the immune system.
-
Curated cancer care
UNC Lineberger researchers are using CAR-T to create better and personalized cancer treatments in one of the largest cell therapy facilities on the East Coast.
-
Thomas C. Shea Clinical Cancer Symposium brings together national leaders in blood cancers
The inaugural symposium featured talks on adoptive cellular therapy for lymphoid malignancies and novel approaches for the treatment of acute myeloid leukemia, myelodysplastic syndromes and myeloproliferative neoplasms.
-
Questions and answers about CAR-T therapy
CAR-T immunotherapy uses your body’s own immune system to help fight cancer. Jonathan Serody, MD, and Natalie Grover, MD, answer some common questions people have about this treatment.
-
Parents, supporters create new fund for CAR-T therapy
Inspired by the potential of immunotherapy in solid tumor cancers, Tom and Nancy Chewning established a fund to support Jonathan Serody, MD, and accelerate his work with CAR-T immunotherapy.